GSK Exits $4.2bn Cancer Drug Deal With Merck KGaA After Multiple Failures
Plug Pulled After Three Trial Flops
GSK is exiting the deal after paying an upfront fee of $360m, but will not have to pay any milestones after bintrafusp's disappointing results. 
